belgium

Green NCAP tests reveal the realworld tradeoffs of electric and combustion cars

LEUVEN, BELGIUM – Green NCAP testing highlights the trade-offs drivers of both electric and petrol-powered cars can face.New tests on…

2 days ago

Mercedes star shines bright as Euro NCAPs final results deliver safer options for every buyer

LEUVEN, BELGIUM – Euro NCAP’s independent assessment of the new CLA shows an outstanding safety performance with a five-star result…

1 week ago

European Protected Waveform Consortium Achieves Major Milestone with Successful Over-the-Air Testing

Demonstration underscores Europe's commitment to secure, resilient, multi-orbit military satellite communicationsSINT-NIKLAAS, Belgium, Dec. 10, 2025 /PRNewswire/ -- ST Engineering iDirect's EU…

1 week ago

Euro NCAPs SAFER TRUCKS Programme wins Prince Michael International Road Safety Award 2025

Leuven, Belgium – Euro NCAP is proud to announce that its groundbreaking SAFER TRUCKS programme has received the 2025 Prince…

3 weeks ago

Euro NCAP announces 2026 protocol changes to tackle modern driving risks

LEUVEN, BELGIUM – Euro NCAP is making major changes to how it evaluates the safety of new cars to better…

3 weeks ago

Euro NCAP announces test results for 23 new cars

LEUVEN, BELGIUM – The scores are in on Euro NCAP's biggest group test of new cars this year. A total…

4 weeks ago

From range anxiety to charging time: Green NCAP tests show how todays EVs perform in the real world

LEUVEN, BELGIUM – Green NCAP’s latest whole-life assessment of vehicles’ environmental impact addresses drivers’ top concerns over electric cars, including…

1 month ago

adidas reveals largest ever collection of home kits ahead of FIFA World Cup 2026

adidas unveils 22 bespoke home kits, with bold new designs inspired by the respective histories, landscapes and cultures of each…

1 month ago

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed…

2 months ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

2 months ago